Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.49 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.47 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 10/20 | 0.46 |
| ▸ | ACE | P12821 | 8/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572784 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL1908566 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18059572 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18059571 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL609953 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL24404055 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18574633 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL598890 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| Hydrochloric Acid SCHEMBL597844 | 0.99 | GPR88 (0.48) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL7426879 | 0.99 | GPR88 (0.48) | GPR88SRRPSAT1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | claimed |
| CN-118812371-A | Synthesis method of (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid | 杭州科巢生物科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118516422-A | Method for synthesizing Sha Kuba koji intermediate by biocatalysis | 江苏海洋大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-118291560-A | Synthesis method of sabatier intermediate (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4- ((tert-butoxycarbonyl) amino) -2-methyl ethyl valerate | 江苏德源药业股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| CN-118109529-A | Method for biocatalytically synthesizing Sha Kuba- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl ethyl valerate serving as Sha Kuba yeast intermediate | 江苏海洋大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-118109528-A | Method for biocatalytically synthesizing Sha Kuba- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid serving as Sha Kuba yeast intermediate | 江苏海洋大学 | 2024-05-31 | — | — | CN | disclosed |
| US-11786498-B2 | Sacubitril calcium salts | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3611160-B1 | AMMONIUM CARBOXYLATE COMPOUND, CRYSTAL FORM AND AMORPHOUS SUBSTANCE THEREOF, AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GPR88 2716/4885SRR 107/4885PSAT1 3815/4885 |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | GPR88 2050/4885SRR 911/4885PSAT1 2304/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | GPR88 2050/4885SRR 911/4885PSAT1 2304/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | GPR88 1307/4885SRR 527/4885PSAT1 3675/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | GPR88 2716/4885SRR 107/4885PSAT1 3815/4885 |
| US-11786498-B2 | Sacubitril calcium salts | DNPEP, BPGM, CACNA1S | GPR88 3217/4885SRR 409/4885PSAT1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.